Articles tagged with Breast Cancer
Researchers at Johns Hopkins Medicine discover that tumor cells can spread through lymphatic vessels by releasing signaling molecules, which attract and facilitate the growth of new blood vessels. The HIV drug maraviroc blocks these signals, preventing breast cancer metastasis when combined with a VEGF-blocking drug.
Scientists at UC San Diego have identified the UBC13 enzyme as a key regulator of breast cancer metastasis, allowing them to potentially block the spread of the disease. The study found that inhibiting this enzyme may prevent metastasis in breast cancer cells.
A large study found that breast cancer patients with bilateral mastectomy did not have better survival rates than those who underwent lumpectomy plus radiation. The study analyzed nearly 190,000 California women and found a slightly lower survival rate among those who had unilateral mastectomy.
CPRIT awards UT Southwestern $26 million to expand cancer screenings, investigate therapy effectiveness, and conduct cancer biology research. The grants also support recruitment efforts and innovative approaches to improve treatment and prevention of cancer.
A third of women in the UK breast screening program do not fully understand the risks of 'overdiagnosis', despite being informed about the concept. Research found that intentions to attend screening remained high despite uncertainty about the information provided.
Researchers at Massachusetts General Hospital found that CTC clusters are associated with poor prognosis and metastatic potential. The presence of CTC clusters in the blood of cancer patients may identify a novel target for therapy.
Researchers recommend using fluorochemicals only where absolutely essential, citing links to cancer, immune system damage, reproductive issues, and environmental contamination. They urge producers to test alternatives properly before market release.
Researchers developed a genomic-based system, IntClust, to classify breast cancer subtypes with high accuracy. The new system identified previously unnoticed subgroups of tumors, including those resistant to treatment, potentially leading to early detection and targeted therapies.
Kids Konnected and the Breast and Gyn Health Project in California will each receive $8,500 awards to support their work assisting cancer patients and their families. The organizations will also be featured at ASTRO's Annual Meeting in San Francisco.
Researchers at UNC Lineberger Comprehensive Cancer Center have developed a new integrated approach to pinpoint genetic drivers of cancer, identifying eight genes linked to luminal breast cancer. These findings offer hope for personalized medicine and potential targeted therapies.
Researchers identify protein p66ShcA as a biomarker for predicting breast cancer outcomes and identifying poor-prognosis cancers. The discovery aids understanding of epithelial to mesenchymal transition, a process enabling tumor cells to metastasize.
Researchers estimated the risk of premature menopause in women treated for Hodgkin lymphoma, providing precise estimates based on treatment types and ages. The study found that certain treatments, such as ovarian radiotherapy and chemotherapy, significantly increased the risk of early menopause.
The European Society for Medical Oncology (ESMO) recognizes the contributions of three outstanding individuals in cancer research and treatment. Carsten Bokemeyer receives the ESMO Award for his work on malignant germ cell tumours, while Peter Boyle wins the Lifetime Achievement Award for his long-standing contribution to cancer epidem...
A new study found that women with severe disabilities are screened for breast cancer less often, at 61%, compared to those with moderate disabilities, who were screened more frequently. This disparity highlights the persistence of health disparities in breast cancer screening, particularly among vulnerable populations.
A study at Huntsman Cancer Institute found compound mutations containing T315I confer complete resistance to all available TKIs, highlighting the need for new treatment options. Researchers have created a dataset that can help clinicians decide which drug will be most effective for each mutation combination.
A study published in JAMA Surgery found that only 24.8% of women who underwent mastectomy in the US had breast reconstruction, with factors including race, education level, and age being significant predictors. The main reasons for not undergoing reconstruction were avoiding additional surgery or feeling reconstruction was not important.
Researchers have identified a biomarker, STAT3 protein, strongly associated with basal-like breast cancer, a highly aggressive and resistant carcinoma. This finding suggests a potential target for new therapeutics designed to treat this deadly cancer subtype.
Scientists have identified a novel gene that predicts both breast cancer relapse and response to chemotherapy, enabling doctors to classify patients for more effective treatment. The discovery could help reduce metastasis and increase the effectiveness of chemotherapy.
Researchers at Loyola University Chicago Stritch School of Medicine discovered that dasatinib causes cancer cells to clump together, preventing metastasis. The drug targets a protein called BCR-ABL found in various malignancies, including breast and skin cancers.
Researchers, led by UC Santa Cruz's Seth Rubin, are developing a new class of drugs to treat breast cancer by targeting the inactivated retinoblastoma tumor suppressor protein. The innovative approach may have fewer toxic side effects and be less vulnerable to drug resistance.
Research at VHIO confirms Myc inhibition as a sound and effective therapeutic strategy for glioma, with no evidence of resistance or side effects. The study reveals new insights into the biology of Myc and its potential to halt normal cell division, leading to tumor cell death.
Researchers have found that an antibody against EphA3 can slow tumour growth and kill cancer cells by disrupting blood vessels and the tumour micro-environment.
Regular use of aspirin or other NSAIDs has been found to reduce the risk of hormone-related breast cancer recurrence by half in overweight and obese women. The study suggests that limiting inflammatory signaling may be an effective approach to altering the cancer-promoting effects of obesity.
Researchers found that NSAID use reduces ERα positive breast cancer recurrence by 50% and extends patients' disease-free period by more than two years. The study suggests a new possibility for reducing breast cancer recurrence among overweight and obese postmenopausal women.
Researchers at Trinity College Dublin found that women taking regular aspirin before diagnosis had lower rates of breast cancer spreading and death. The study suggests a possible link between aspirin use and reduced mortality from breast cancer, with further research needed to understand the mechanism and optimal dosage.
Researchers found that patients taking COX2 inhibitors, such as aspirin or ibuprofen, had a lower breast cancer recurrence rate compared to those not taking these medications. This reduced the risk of ERα positive breast cancer by 50% and extended disease-free periods by more than two years.
Regular exercise, including brisk walking, is associated with a lower rate of breast cancer in African American women. Women who exercised vigorously for seven or more hours each week were 25% less likely to develop breast cancer compared to those who exercised less.
A UK study published in The Lancet found that being overweight or obese increases the risk of developing 10 common cancers, with over 12,000 cases estimated each year in the UK. The study also estimates that a population-wide 1 kg/m² increase in average BMI could result in an additional 3,790 cases annually.
A phase I clinical trial for MicroVAX's cancer vaccine has begun in Singapore, assessing safety and immune response against breast, prostate, colon, ovary, and lung cancers. The vaccine targets a common protein on many types of cancer.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that postmenopausal women who exercised at least four hours of walking per week had a 10% decreased risk of invasive breast cancer. The benefits of regular physical activity were rapid and short-lived, disappearing if exercise stopped.
Researchers discovered that breast cancer cells exploit a signaling pathway used by normal mammary stem cells during pregnancy to produce faster-growing, more aggressive tumors. This connection may contribute to the increased short-term risk of highly aggressive breast cancers following each pregnancy.
A study of postmenopausal women found no link between bisphosphonate treatment and reduced breast cancer risk. Researchers analyzed data from two randomized trials, concluding that bisphosphonates do not protect against breast cancer in this population.
A new study led by researchers at UCSF analyzed the effect of two widely used osteoporosis drugs on breast cancer risk in post-menopausal women. The findings suggest that low estrogen levels, rather than the drugs themselves, may be protecting against breast cancer.
A comprehensive analysis of data from thousands of patients revealed that one in ten cancers would be classified differently using a new classification system based on molecular subtypes. The study provides a more refined, quantitative picture of cancer subtypes and could lead to different treatment options for those patients.
A new study analyzing over 3,500 tumor samples reveals that many cancers can be classified differently based on cellular and molecular criteria. The research suggests that patients may benefit from more accurate diagnoses and tailored treatments, with potential implications for personalized cancer therapy.
Researchers analyzed over 3500 tumors using multiple genomic platforms, revealing that cancers are more likely to be molecularly and genetically similar based on their cell type. The study proposes a new classification system that could lead to personalized cancer treatment and eligibility for novel therapeutics.
Researchers have completed the largest cancer genetic analysis ever conducted, revealing a new way of classifying cancers. The study found that one in 10 cancers would be classified differently using this new approach, which could lead to better treatment options for patients.
Researchers have uncovered a new gene fusion that may contribute to the development of luminal B breast cancer, a subtype associated with more aggressive forms and higher recurrence rates. The study found that this fusion is present in approximately 8% of tumor samples and can lead to increased cell motility and invasion.
A study published in the New England Journal of Medicine found that women with mutations in the PALB2 gene have a one in three chance of developing breast cancer by age 70. The study analyzed data from 154 families and found that risks were higher for those with family history of breast cancer.
A new study published in Radiology suggests that mammography screening for women over 75 may reduce the rate of more advanced breast cancers, leading to improved survival rates. Mammography-detected invasive breast cancer patients had a 10% reduction in mortality after five years.
A recent study published in the Journal of Clinical Oncology suggests that patient navigation can lead to better breast cancer care for high-risk populations, including minority women. Researchers found that patients assisted by trained navigators were more likely to start recommended treatments, such as hormonal therapy.
Researchers at MD Anderson Cancer Center have discovered that protein ZEB1 helps breast cancer cells repair DNA damage caused by radiation therapy, making them more resistant to treatment. This finding has significant implications for the development of new treatments targeting ZEB1 and other proteins involved in radioresistance.
Researchers have found a link between tumor suppressor mutations and missing segments of genetic material in squamous cell head and neck cancers. The study suggests that treating tumors with both markers may intensify treatment, while those with only one marker may benefit from de-intensified treatment.
A recent study published in Cancer Research found that women who recently used birth control pills containing high-dose estrogen had an increased risk for breast cancer. The study suggests that this risk may vary by oral contraceptive formulation, and it is essential to consider the established health benefits of oral contraceptive use...
A University of Houston study found that expressive writing can reduce fatigue, intrusive thoughts, and posttraumatic stress in Chinese-speaking breast cancer survivors. The intervention involved writing about emotions and benefits for 20 minutes each week over three weeks.
Researchers found that HSF1 activates a transcriptional program in both cancer cells and stromal cells, fueling malignant processes. HSF1 activation is associated with poor patient outcomes in breast and lung cancers, making it a potential biomarker for predicting tumor progression.
A study found that acupuncture significantly improved the quality of life for early-stage breast cancer patients taking aromatase inhibitors by reducing fatigue, anxiety, and depression. The intervention led to a significant reduction in these symptoms, with effects persisting for at least four weeks after treatment.
Researchers at Dana-Farber Cancer Institute found that subgroups within tumors drive growth, rather than the fastest-proliferating cells. Targeting these growth-driving cells could improve treatment outcomes and prevent tumor expansion.
Researchers will map out BRCA1 protein structures in healthy and mutated forms to identify molecular targets for new treatments. The goal is to improve treatment options for women with hereditary breast cancer.
Researchers discovered two distinct molecular clocks operating at different stages of tumor growth, with implications for chemotherapy resistance and prognosis. The study used single-cell genome sequencing to profile thousands of cells, providing insights into genomic diversity and its potential clinical applications.
Research suggests that dim light exposure at night can suppress melatonin production in rats with human breast tumors, making them resistant to the breast cancer drug tamoxifen. However, giving these rats a melatonin supplement during the night restored their tumor sensitivity to the drug.
A new study by Tulane University reveals that exposure to light at night can render breast cancer cells resistant to tamoxifen. In contrast, complete darkness and high melatonin levels significantly slow tumor growth and enhance tamoxifen's effectiveness.
A Cincinnati Cancer Center study finds that SapC-DOPS, a combination of lysosomal protein saposin C and phospholipid DOPS, targets and kills cancer cells, including those from breast and lung cancers. The treatment showed promise in animal models, with some tumors completely cured within 24 hours.
Researchers have identified three genetic changes linked to an increased risk of breast cancer in East Asian women. These findings provide new insights into the genetics and biology of breast cancer.
Researchers found that bioidentical hormone treatments reduced tumor recurrence and improved cardiovascular and bone health, while also increasing physical activity and cognition. The study's results are promising but require further validation, providing a new direction in the search for alternative hormone therapies.
A multi-disciplinary team of scientists has discovered that a gene called MED12 is altered in nearly 60% of fibroadenomas, the most common benign breast tumours diagnosed in women. The study's findings have potential applications in distinguishing fibroadenomas from breast cancer and developing targeted therapies.
Researchers at Yale University developed a diagnostic test to detect PD-L1 expression in early-stage breast cancers, with 60% showing high levels of PD-L1 and tumor-infiltrating lymphocytes. High levels predicted better survival rates for patients, suggesting an immune system's role in controlling these cancers.
A decade of research led by Dr. Tak Mak identified PLK4 as a promising therapeutic target for breast cancer treatment and developed a small molecule inhibitor to block it. The study showed significant antitumor activity in preclinical models, offering hope for personalized cancer medicine.
Huntsman Cancer Institute will become a key partner in the National Clinical Trials Network, providing access to clinical trials for patients across the Intermountain West region. The institute's unique research assets, including the Utah Population Database and Center for Quantitative Imaging Excellence, will enable multi-institutiona...
A recent study published in JNCI: Journal of the National Cancer Institute found that contralateral prophylactic mastectomy (CPM) may confer only a marginal life expectancy benefit depending on the type and stage of cancer. The procedure was more beneficial for younger women and those with stage I and ER-negative breast cancer.